StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Research analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ:AKTX opened at $1.26 on Tuesday. The business has a 50-day moving average of $1.25 and a two-hundred day moving average of $2.51. Akari Therapeutics has a 12 month low of $0.90 and a 12 month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.